Personal injury lawyers at Messa & Associates, P.C. have recently come across news stating that Globus Medical Inc., a spinal implant manufacturer, will pay the U.S. Food and Drug Administration $1 million in penalties for selling its NuBone Osteoinductive Bone Graft product after the FDA rejected the device in 2009.
The FDA learned that Globus was distributing the NuBone Osteoinductive, despite being told that the medical device was not substantially equivalent (NSE) to legally-marketed products, during a September 2010 inspection. The company also ignored multiple warnings given by the FDA to stop selling the device, according to a commissioner for regulatory affairs.
The settlement requires Globus Medical to pay a $550,000 penalty fee and the company’s CEO, David Paul, to pay an additional $450,000 fine.
Personal Injury Lawyers: FDA Approval Process Required NuBone Osteoinductive Devices to Be Substantially Equivalent
The FDA currently uses two procedures to approve medical devices. Clinical trials are necessary to get approval for more critical devices. However, Globus Medical’s NuBone Osteoinductive is considered a medical device that poses a lower level of risk to patients. Therefore, Globus Medical was only required to show that the NuBone Osteoinductive was substantially equivalent to similar medical devices that are already on the market.
Personal Injury Lawyers in Philadelphia and New Jersey
The Philadelphia personal injury lawyers at Messa & Associates are experienced at handling cases involving pharmaceutical and medical device injuries. Our extremely skilled team of personal injury lawyers and medical experts is dedicated to ensuring you receive proper compensation for your personal injuries. If you have been injured by a defective medical device, a negligent medical provider, or have endured any other type of personal injury, contact the personal injury lawyers of Messa & Associates for a free consultation. Call toll free at 1-877-MessaLaw, or submit a free online inquiry.
For immediate assistance, click the CHAT LIVE button to your right.
When a cleft does not affect the mouth’s palate structure it is referred to as cleft lip. Cleft lips can occur on one or both sides of the lip which are generally referred to as unilateral or bilateral clefts. The first category of cleft lip is known as an incomplete cleft. An incomplete, or partial, cleft lip occurs at the top of the lip. The cleft appears as a small gap or indentation that does not reach the nose.
Women frequently use Topamax because they are much more likely to suffer from severe migraine headaches as opposed to their male counterparts. In fact, women are three times more likely than men to encounter migraines. Women who are looking to become pregnant face an additional risk. In their childbearing years, the likelihood of headaches increases yet again, making women of this age extremely vulnerable. Therefore, it is quite understandable that many women would turn to a well respected product, such as Topamax, to alleviate pain. The problem that has now surfaced is that Topamax has been linked to certain birth defects such as cleft lip or cleft palate. Although Topamax is a proven commodity that deals well with ailments such as epilepsy and migraines, the risk of potential birth defects in pregnant women may lead them to search for alternatives. The FDA and birth defect lawyers both agree, Topamax should not be prescribed for pregnant women in most cases.
On September 13, 2010, the U.S. Department of Health and Human Services Food and Drug Administration issued FDA Recall No. Z 2409 010 entitled “NexGen Complete Knee Solutions MIS Tibial Components, Locking Screw and Stem Extensions” recall notice. This recall notice can be found at the
Knee replacement surgery, following the success and failures of hip replacement surgery, became more commonplace in the 1960s and the 1970s. It was billed as safe, effective, and an enormous benefit to any patient with osteoarthritis. Since that time, as with hip replacement surgery, knee replacement joint technology is constantly changing and modifying in an effort to improve patient outcomes in knee replacement patients.